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Lavender essential oil is traditionally used and approved by the European Medicines
Agency (EMA) as herbal medicine to relieve stress and anxiety. Some animal and clinical
studies reveal positive results in models of anxiety and depression although very little
research has been done on molecular mechanisms. Our work consisted of evaluating
the effects of lavender (Lavandula angustifolia) essential oil on central nervous system
well-established targets, such as MAO-A, SERT, GABAAand NMDA receptors as well
as in vitro models of neurotoxicity. The results showed that lavender essential oil and its
main components exert affinity for the glutamate NMDA-receptor in a dose-dependent
manner with an IC50 value of 0.04µl/mL for lavender oil. In addition, lavender and linalool
were also able to bind the serotonin transporter (SERT) whereas they did not show affinity
for GABAA-benzodiazepine receptor. In three different models of neurotoxicity, lavender
did not enhance the neurotoxic insult and improved viability of SH-SY5Y cells treated with
hydrogen peroxide. According to our data, the anxiolytic and antidepressant-like effects
attributed to lavender may be due to an antagonism on the NMDA-receptor and inhibition
of SERT. This study suggests that lavender essential oil may exert pharmacological
properties via modulating the NMDA receptor, the SERT as well as neurotoxicity induced
by hydrogen peroxide.
Keywords: essential oils, central nervous system, lavender, Lavandula angustifolia, Lavandula officinalis,SH-SY5Y
cells, glutamate receptor
INTRODUCTION
Essential oils have a long tradition in pharmaceutical sciences as natural products with
pharmacological, cosmetic, agrochemical and nutritional applications (Bakkali et al., 2008). The
use of EO in form of aromatherapy or phytotherapy is widely extended, some of them being
used as agents to relieve anxiety and stress (Setzer, 2009). Phytotherapy consists of the use of
medicinal plants in order to prevent, cure or threat illnesses. Aromatherapy can be understood as
a subdivision of phytotherapy and defined as the use of essential oils regarding therapeutic effects.
Abbreviations: CNS, central nervous system; LEO, lavender essential oil; GABA, γ-aminobutyric acid; iGLURs, ionotropic
glutamate receptors; MAO-A, monoamine oxidase A; NMDA, n-methyl-D-aspartate; SERT, serotonin transporter; SSRI,
selective serotonin reuptake inhibitor.
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These products have been used for centuries and are accepted in
traditional or modern healthcare systems of medicine. Medicinal
plants are widely used for the treatment of central nervous system
disorders (Wheatley, 2005) but in some cases there is still lack of
preclinical and clinical studies.
Central nervous system disorders have a great impact in
society due to a general aging process of the population as well
as lifestyle. Stress is one of the most prevalent psychological
disorders in developed countries leading to other clinical
features, such as anxiety, insomnia or depression.
Benzodiazepines (BZD) and selective serotonin reuptake
inhibitors (SSRIs) are highly prescribed as anxiolytic and
antidepressant drugs, respectively. BZD, such as diazepam,
lorazepam or alprazolam produce calming effects via binding
to GABAA receptors, but they may also produce somnolence
and cognitive impairment as adverse drug reactions. SSRIs
(e.g., fluoxetin, paroxetin, citalopram) are prescribed as
antidepressants because they are able to selectively block the
serotonin transporter (SERT), but side effects include sexual
dysfunction and neuropsychiatric disorders, such as suicide
tendencies and sleep disorders. Both groups of medicines are
also involved in withdrawal and “rebound effects” as a result of
discontinuing their administration.
Certain EO are being used as anxiolytic remedies and the
administration mode can be orally but also by inhalation or
combined with massage. One of the most popular essential
oils for mental disorders and anxiety is lavender (Lavandula
angustifolia Miller or Lavandula officinalis Chaix). Lavender
essential oil can be considered as one of the best-seller over
the counter herbal remedies for anxiety, stress and depression.
Studies reveal high content of linalool and linalyl acetate (Da
Porto et al., 2009) and international organizations, such as the
World Health Organization (WHO), the European Scientific
Cooperative on Phytotherapy (ESCOP) or the European
Medicines Agency (EMA) approve this medicinal plant to relieve
stress, restlessness and anxiety (Community)1.
The growing awareness of the adverse effects of central
nervous system drugs has led to develop new strategies and
safer pharmacological agents in mental health. Enzymes, such
as monoamine oxidase (MAO), proteins, such as the SERT and
ligand-gated ion channels, such as GABAA and NMDA receptors
are therapeutic targets in neuropharmacology. With the aim to
contribute to evidence-based herbal medicine we have studied
the effects of lavender essential oil on pharmacological targets
involved in anxiolytic and antidepressive properties as well as
in vitromodels of neurotoxicity.
METHODS
Lavender Essential Oil (LEO) and
Chemicals
Pure lavender (L. angustifolia) essential oil was kindly supplied
by Pranarom International (Belgium). Isolated monoterpenes
(linalool, linalyl acetate) were purchased from Fluka. Enzymes,
1 Community herbal monograph on Lavandula angustifolia Mill., aetheroleum.,
EMA/HMPC/143181/2010 (http://www.ema.europa.eu/ema/).
proteins and reagents were acquired from Sigma. Linalool and
linalyl acetate were also tested when lavender essential oil had a
clear and significant activity in the assays.
Chemical Profile by GC-MS
Although the essential oils are chemically characterized by
Pranarom International, LEO was analyzed in the laboratory by
GC-MS on an Agilent 6890N Network GC system coupled to
a 5973 Network Mass Selective Detector, accelerating voltage -
69.9 eV, recodingmasses of 35.00–400.00. GC conditions: injector
temperature: 150◦C; temperature programme: start 50◦C,
20◦C/min to 300◦C; column: HP5MS (5% phenylmethylsiloxane)
capillary, 30.0m × 250µl × 0.25µm nominal. Carrier gas:
helium at 1.0ml/min. A NIST library was used for comparison
of MS data.
Animals and Brain Membrane
Homogenates
Adult male Sprague Dawley rats were obtained from Taconic
(Denmark). Ethical permission for the studies was granted by the
AnimalWelfare Committee, appointed by the DanishMinistry of
Justice, and all animal procedures were carried out in compliance
with the ECDirective 86/609/EEC and theDanish laws regulating
experiments on animals. Rats were put down by competent staff,
the heads were separated from the body and the brains were
removed whereas cerebellum was discarded. The cortex were
weighed and homogenized with an Ultra-Turrax using different
buffers at 4◦C and the tissue preparation in each case was carried
out as earlier described (Ransom and Stec, 1988). The tissue
homogenates were resuspended and stored in aliquots at −80◦C
until use.
Bioassays Regarding Serotonergic Targets
Monoamine Oxidase-A Inhibition (MAO-A Assay)
The bioassay was performed in a 96-well microplate (Saaby
et al., 2009). Each well contained 50µl of essential oil dilution
or DMSO as blank (making a final concentration in the
wells of 0.002, 0.01, 0.02, and 0.1%), 50µl of chromogenic
solution (0.8mM vanillic acid, 417mM 4-aminoantipyrine and
4 U/ml horseradish peroxidase in potassium phosphate buffer
pH 7.6), 100µl of 3mM tyramine and 50µl of 8 U/ml MAO-
A. Absorbance was read at 490 nm every 5min for 30min.
Background interferences were deducted in the same way
described above but without MAO enzyme. Data was analyzed
usingGraphPad Prism. IC50 values could not be obtained because
the higest tested concentration did not reach 50% of MAO
inhibition. Clorgyline was used as positive control.
Serotonin Transporter Assay ([3H]-Citalopram
Binding Assay)
The assay was performed on the basis of themethod fromNielsen
et al. (2004). 25µl of three different essential oil concentrations
were mixed with 50µl of 4 nM [3H]-Citalopram and 225µl
of rat cortex suspension making a final concentration of the
essential oils in the assay of 0.08, 0.4, and 0.8%. All components
were previously dissolved in buffer (50mM Tris-base; 120mM
NaCl: 5mM KCl at pH 7.5). Plastic tubes were placed on an
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ice bath, the reagents were added and the tubes were mixed
and then left at room temperature (approximately 22◦C) for
2 h. After incubation, 5ml of ice cold buffer were added to
the samples and they were filtered through GC-50 Advantec
glass filters under vacuum and immediately washed once with
additional 5ml of ice cold buffer. Control test tubes (with
buffer instead of EO) and blind tubes (with 25µl of 120µM
paroxetine instead of EO) were done in every run in order
to determine total and unspecific binding. The amount of
radioactivity was determined transferring the glass filters into
scintillation tubes and adding 4ml of Ultimo Gold XR. The
scintillation tubes were placed in the dark for 30min before
they were measured on a Tri-CARB 2100 TR analyzer. Three
independent experiments were performed in triplicates. Non-
radioactive citalopram was used as reference. Linalool and linalyl
acetate were tested. The specific binding of [3H]-citalopram was
determined using the formula: % binding = [dpm(essential oil)-
dpm(unspecific binding)/dpm(total binding)-dpm(unspeficic binding)] ×
100.
Bioassays on Ionotropic Receptors
Affinity for GABAA Receptor ([
3H]-Ro 15-1788
Binding Assay)
The membrane preparation was washed with ice-cold buffer
(50mM Tris-citrate pH 7.1). The suspension was centrifuged at
0–4◦C for 10min at 27,000 × g. The pellet was resuspended in
Tris-citrate buffer (2mg original tissue per ml) and used for the
assay. 25µl of 3H-Ro 15-1788 (flumazenil) was added to 25µl
of test solutions (10, 1, and 0.1mg/ml) and 500µl of membrane
preparation. Total and unspecific binding was measured using
buffer or diazepam (1µM assay final concentration). After
incubation for 40min in an ice bath, 5ml of ice-cold buffer was
added to the samples and poured onto Adventic glass fiber filters
(GC-50) under vacuum, and immediately washed with another
5ml of ice-cold buffer. The amount of radioactivity of the filters
was measured by conventional liquid scintillation counting using
Ultimo Gold XR as scintillation fluid. Clonazepam was used as
positive control.
Affinity for NMDA Receptor ([3H]-CGP39653 Binding
Assay)
Affinity for native NMDA receptors was determined using 2 nM
[3H]-CGP 39653 (Sills et al., 1991) with some modification. On
the day of the assay, frozen membranes were quickly thawed
and homogenized in 30 volumes of ice-cold Tris-HCl buffer,
pH 7.4 (50mM containing 2.5mM CaCl2), and centrifuged
(48,000 × g for 10min). This step was repeated three times. The
final pellet was re-suspended in ice-cold buffer, corresponding
to approximately 0.4–0.5mg protein/ml. Binding was carried
out in aliquots consisting of 25µL [3H]-CGP 39653, 25µL test
solution, and 200µL membrane suspension and incubated at 0◦
for 60min. Non-specific binding was determined using 1mM
(S)-Glu. Binding was terminated by filtration through Whatman
GF/C filters using a 96-well Packard Filter-Mate Cell Harvester
and filters were washed with 3× 250 µL of ice-cold buffer. After
drying, 30µL Microscint 0 (Perkin-Elmer) per well was added
and the filter was counted on a Topcounter (Perkin-Elmer).
Linalool and linalyl acetate were also tested in this assay.
Neuroprotection on SH-SY5Y Cells
SH-SY5Y Neuroblastoma Cell Culture
Cells were cultured in DMEM (Gibco, ref. 41966-029) containing
phenol red (PR), L-Glutamine (1mM) and sodium pyruvate
(1mM) and was supplemented with 10% FBS (Gibco), penicillin
(100 U/mL, Gibco) and streptomycin (100 U/mL, Gibco). Cells
were maintained at 37◦C in saturated humidity (5% CO2). Non-
differentiated cells were plated on 48-well plates (Corning), at a
density of 5× 104 cells per well and were used 48 h after seeding.
Aβ25–35SolubleSpecies Preparation
Aβ25–35fragment was purchased from Sigma-Aldrich
laboratories (ref. A4559-1MG). 1mg of Aβ25–35 fragment
was dissolved in 1mL of type II water and was frozen at -20◦C
until further use. Different concentrations of Aβ25–35 (5, 10
and 15µM) were incubated in DMEM phenol red free (Gibco,
31053-028) at 37◦C for 3 days to obtain the oligomeric forms.
Cell Treatment and MTT Cell Viability Assay
SH-SY5Y cells were treated with either different LEO
concentration (0.05, 0.1, 0.5, and1µL/mL) or incubation
time (0, 2, and 24 h), followed by hydrogen peroxide (100, 200,
400, 800, and 1,600µM), malonate (0 or 50mM) or Aβ25–35(5,
10, and 15µM).
Cell viability was examined by the 3,4,5-dimethylthiazol-2-
yl-2,5-diphenyltetrazolium bromide (MTT) assay. MTT assay
is a colorimetric assay for measuring the activity of cellular
enzymes in living cells in response to potential toxic. After the
cell treatment, culture medium was replaced by a solution of
5 mg/mL MTT (Sigma-Aldrich) in DMEM (Gibco, 31053-028).
Cells were incubated with MTT solution for 2 h in the cell
incubator (5% CO2 and 37
◦C). Then, the MTT solution was
discarded and DMSO was added to the wells. Aliquots were
transferred to a 96-well plate, and absorbance was measured at
595 nm in a plate reader. Results were expressed as percentages
of non-treated control cells.
Statistical Analyses
Data are expressed as mean ± SE (figures) or as mean ±SD
(tables) of at least three independent experiments performed in
different days and in triplicates. GraphPad Prism was used to
calculate IC50 values and to detect significant differences. Student
t-test or ANOVA was performed for data analysis.
RESULTS
Chemical Profile by GC-MS
According to the GC-MS analyses, lavender essential oil mainly
contained the following monoterpenes: linalyl acetate (52.1%),
linalool (37.4%), geranyl acetate (5.4%), and β-caryophyllene
(5.1%).
Monoamine Oxidase-A Inhibition (MAO-A
Assay)
Inhibition of MAO A was not detected (data not shown).
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TABLE 1 | Activity of lavender essential oil (LEO) on the serotonin
transporter (SERT) and GABAA ionotropic receptor.
Samples SERT (% 3H-Citalopram binding)
0.8µl/ml 4µl/ml 8µl/ml




LEO 100.3 ± 9.5 100.1 ± 0.8 105.2 ± 9.3
*p< 0.05; ***p< 0.001 vs. the lowest concentration tested (0.8µl/ml in the SERT assay or
0.045µl/ml in the GABA assay). Data are mean ± SD of three independent experiments
performed in triplicates.
FIGURE 1 | Percentage of 3H-Citalopram binding induced by different
concentrations of linalool on the SERT assay. Linalyl acetate did not
show affinity to the serotonin transporter (data not shown). ***p < 0.0001 vs.
the lowest concentration tested.
Serotonin Transporter Assay
([3H]-Citalopram Binding Assay)
The effects of LEO on the SERT are displayed in Table 1,
showing moderate activity in this assay (citalopram IC50
value was 1.3 nM). LEO significantly displaced 3H-citalopram
from binding to the SERT in a dose-dependent manner,
which means that LEO might have an antidepressant-
like effect via this specific transporter. This effect was
also detected for linalool, one of the main constituents
of lavender essential oil (Figure 1), but not for linalyl
acetate.
Affinity for GABAA Receptor ([
3H]-Ro
15-1788 Binding Assay)
The affinity for the GABAA-benzodiazepine receptor, which
may lead to a nerve calming effect, was not detected (Table 1).
LEO had no effect in binding this ionotropic receptor.
Clonazepam (IC500.002 nM) was used as positive control
drug.
FIGURE 2 | Affinity of lavender essential oil (A) and linalool and linalyl
acetate (B) for the glutamate NMDA receptor. The displacement studies of
[3H]CGP39653 were performed on membranes obtained from rat brain
homogenates.
TABLE 2 | IC50 and Ki values of lavender essential oil (LEO) and
monoterpenes in the [3H]CGP39653 binding assay.
Essential oil IC50 (µl/ml) Ki (µl/ml)
LEO 0.04 ± 0.09 0.026 [0.022;0.030]
Monoterpenes IC50 (mM) Ki (mM)
Linalyl acetate 0.74 ± 0.18** 0.54 [0.47;0.62]
Linalool 2.97 ± 0.63 2.3 [2.1; 2.6]
**p < 0.01 vs. linalool; each IC50 value, determined from the “dose-response” curve, has
been converted into the Ki value using the Cheng Prusoff equation: (Ki = IC50 × [1/([L]/KD )
+ 1)]. (S)-Glu has a Ki value of 0.02µM.
Affinity for NMDA Receptor (CGP39653
Binding Assay)
Lavender Essential Oil (LEO) was found to be active
in the CGP39653 binding assay. Figure 2 shows the
profile of the affinities for the NMDA receptor and
Table 2 presents results in terms of IC50 and Ki values.
It can be observed that lavender was significantly active
showing a clear dose-response activity (Figure 2A). In
this case, linalool and linalyl acetate were also tested,
showing binding properties to the NMDA receptor
(Figure 2B).
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FIGURE 3 | Effect of 1µl/ml lavender essential oil (LEO) on hydrogen
peroxide induced toxicity on SH-SY5Y cells at 0 (A), 2 (B),and 24 h (C).
*p < 0.05 vs. medium only.
Effects of Lavender Oil against Hydrogen
Peroxide in SH-SY5Y Cells
As depicted in Figure 3A, when 1µl/ml lavender oil was
incubated 0 h before the addition of hydrogen peroxide
(H2O2), lavender oil only produced a significance difference
(∗p < 0.05, Two-way ANOVA) at 1,600µM of H2O2.
Same result was obtained when lavender oil was incubated
2 h prior the addition of H2O2 (
∗p < 0.05, Two-way
ANOVA) (Figure 3B). As shown in Figure 3C, when
lavender oil was incubated 24 h prior the addition of
H2O2 a significant reversion of cell death was obtained at
400, 800, and 1,600µM of H2O2 (
∗p < 0.05, Two-way
ANOVA).
Effects of Lavender Oil against Malonate in
SH-SY5Y Cells
Lavender oil did not protect from malonate induced
toxicity in any of the concentrations (0.05, 0.1, 0.5,
and 1µL/mL) or incubation times tested (0, 2, or 24 h;
Figure 4).
FIGURE 4 | Effect of lavender essential oil on malonate induced
toxicity on SH-SY5Y cells at 0 (A), 2 (B), and 24 h (C). ****p < 0.0001 vs.
0mM malonate in the respective lavender concentration.
Effects of Lavender Oil against Aβ25–35 in
SH-SY5Y Cells
As observed in Figure 5, lavender oil only produced a significant
effect against Aβ25–3515µM induced toxicity when it was
incubated 2 h before toxin addition (∗∗p < 0.01, Two-way
ANOVA; Figure 5B).
DISCUSSION
Lavender is used in pharmacy, phytotherapy and aromatherapy
to treat central nervous system disorders, such as anxiety,
stress, and sleep disorders. This essential oil is one of the best-
selling natural remedies and a common therapeutic tool for
physiotherapists and chiropractors.
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FIGURE 5 | Effect of 1µl/ml lavender essential oil (LEO) on
beta-amyloid induced toxicity on SH-SY5Y cells at 0 (A), 2 (B), and 24 h
(C). **p < 0.01 vs. 15µM beta-amyloid (medium only).
There has recently been an increase in the use of natural
therapies due to well-known side effects of common CNS drugs,
such as (BZD) and selective serotonin re-uptake inhibitors
(SSRI). Although BZD and SSRI have been widely used
in neuropharmacology, there is a need of developing new
therapeutic tools that play a role both in prevention and
treatment of mild CNS disorders.
In this sense, aromatherapy and some essentials oils have been
used for decades to induce nerve-calming effects and mood-
enhancing properties (Dobetsberger and Buchbauer, 2011).
Aromatherapy is a form of complementary and alternative
medicine (CAM) that uses plant essentials oils to affect the mood
or health of the patient (Wheatley, 2005) and some clinical
studies suggest that inhaled or topically applied essential oils
like lavender exert psychological and central nervous system
effects (Perry and Perry, 2006). It has also recently been stated
that essential oils may behave as antidepressants due to playing
an important role on neurotransmitter pathways, mainly in the
serotonin system (Lv et al., 2013).
Certain studies have reported pharmacological properties
of essential oils but there is little research on the molecular
mechanisms underlying the CNS effects. The ability of lavender
essential oil to interact with neuropharmacological targets, such
as MAO-A, the SERT and ionotropic receptors (GABAA and
NMDA) has been tested, as well as the protective potential against
neurotoxic agents, such as hydrogen peroxide, malonate and
amyloid peptide.
It was surprising that LEO had the capacity to bind
to the NMDA receptor, which was measured through the
CGP39653 binding assay. CGP39653 is a competitive antagonist,
being currently the ligand of choice for labeling NMDA
receptors. NMDA receptors are neurochemically classified as
ionotropic glutamate receptors (iGLURs) and are involved in
certain neurological and psychiatric disorders, such as epilepsy,
sustained-seizure damage, Parkinsonism, etc. For this reason
iGLURs are considered pharmacological targets in drug research
and development. LEO was able to displace CGP39653 binding
in a dose-dependent mode, which means that this oil may exert
nerve-calming effects via modulating NMDA receptors. This is
the first time that this affinity is reported and this fact could
explain the anti-agitation properties that have been found for
these products in animal and some clinical studies (Bradley et al.,
2009; Faturi et al., 2010; Kasper et al., 2010; Tsang and Ho,
2010; Woelk and Schlaefke, 2010; Chioca et al., 2011; Goes et al.,
2012; Hritcu et al., 2012; Schuwald et al., 2013). NMDA-receptor
activation by glutamate is also involved in neurotoxicity so our
essential oil might exert neuroprotection through the blockade of
this ionotropic receptor.
According to our data, these results are in the range of other
natural products that have been reported to show activity in this
target (Cho et al., 2001; Pedersen et al., 2008; Marchetti et al.,
2011).
Lavender essential oil has shown activity in animal and
human studies but according to Koulivand et al. (2013), due to
methodological inadequacies, small sample sizes, variations on
administration methods or the absence of placebos or control
groups in the studies, more standard experiments are needed to
confirm the benefits of lavender in CNS disorders. The molecular
mechanisms involved in lavender effects have been suggested
in other studies. For example, Huang et al. (2009) suggest
that lavender essential oil reversibly inhibited GABA-induced
currents in a concentration-dependent manner (0.01–1 mg/mL),
whereas no inhibition of NMDA- or AMPA-induced currents
was noted. In a recent study, Schuwald et al. (2013) identified a
standarized lavender essential oil (Silexan) as a potent anxiolytic
inhibiting voltage dependent calcium channels in synaptosomes,
primary hippocampal neurons and stably overexpressing cell
lines, in the same range as pregabaline.
Lavender essential oil is known to contain monoterpenes like
linalool and linalyl acetate, which seem to be responsible for the
activity according to our data and previous works (Cline et al.,
2008; Linck et al., 2010; Souto-Maior et al., 2011). The capacity of
linalool to interact with the glutamatergic system and the NMDA
receptor is not new as it has been previously described by other
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authors (Elisabetsky et al., 1995, 1999; Silva Brum et al., 2001;
Aprotosoaie et al., 2014); however, the ability of linalyl acetate
to bind the NMDA receptor has not been found to be reported
in previous works. It seems that lavender essential oil anxiolytic
effects is due to the fact that its main monoterpenes, linalool and
linalyl acetate, interact with the NMDA receptor.
It is very difficult to establish structure activity relationships
because linalyl acetate was inactive in the SERT assay, whereas the
activity of this compound was slightly higher than linalool in the
NMDA binding receptor assay. Linalool and linalyl acetate are
secondary metabolites classified as monoterpenes with a similar
structure consisting of a linear hydrocarbon chain of 10 carbons
(linalool) or 11 (linalyl acetate), being linalyl acetate the ester
of linalool. The free hydroxyl group in linalool seems to be
determinant for the activity in the SERT. On the contrary, the
activity on the NMDA receptor is increased when the acetate
group exists in the compound named linalyl acetate; limonene,
another monoterpenic compound found at high concentration
in Citrus essential oils, has also shown anxiolytic-like activity
with other targets involved (de Almeida et al., 2012; Lima et al.,
2013).
Other essential oils have been demonstrated to produce
changes in brain neurotransmitters which could explain its anti-
agitation properties. For example, ylang-ylang (Cananga odorata)
essential oil has shown anxiolytic effects in male mice decreasing
the dopamine concentration in the striatum and increasing the
serotonin concentration in the hippocampus (Zhang et al., 2016).
Surprisingly, linalool is one of the main components of this
essential oil. The essential oils obtained from Eugenia uniflora has
also demonstrated antidepressant-like activities in animal models
with the serotonergic and adrenergic systems being involved
(Victoria et al., 2013). Melissa officinalis essential oil, which is
also used as a natural sedative, has demonstrated a depressant
effect on neurotransmission but no inhibition of NMDA- or
AMPA-induced currents was detected (Abuhamdah et al., 2008).
Citrus aurantifolia (bitter orange) essential oil has also exhibited
anxiolytic-like effects mediated by 5-HT(1A)-receptors (Costa
et al., 2013). All these works put forward the idea that the
serotonergic system is involved in the nerve calming effects of
essential oils.
We have also observed that lavender and linalool inhibits
serotonergic targets, such as the SERT, which might explain why
lavender has shown antidepressant-like effects in animal and
human models (Cavanagh and Wilkinson, 2002; Akhondzadesh
et al., 2003; Hritcu et al., 2012). However, we did not observe
effects on the GABAA-receptor, which is in accordance with
results from a recent study (Chioca et al., 2013).
This study has been completed using neuroblasts from neural
human tissue (SH-SY5Y) exposed to different neurotoxic agents.
Lavender was able to protect the cells from the toxic insult
generated by hydrogen peroxide although it was not capable
to reduce malonate toxicity. Results from amyloid-β peptide
induced toxicity are not conclusive. However, this activity seems
to be in accordance with a previous study where lavender
essential oil showed neuroprotective properties against hydrogen
peroxide induced toxicity in PC12 cells (Xu et al., 2016). The
authors conclude that lavender protected the cells reducing LDH,
NO release, intracellular ROS accumulation and MMP loss.
CONCLUSION
Our study reveals for the first time that lavender exerts receptor
binding affinities with a relevant activity on the NMDA receptor.
According to our data, we can state that the anti-agitation and
antidepressant activities of lavender may be attributed at least in
part to the NMDA receptor modulation as well as an inhibition
of the SERT. Lavender essential oil also protected SH-SY5Y cells
from hydrogen peroxide induced neurotoxicity.
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